Tuan Vu Selected Research

Cholinergic Receptors

2/2024	Efficacy of ravulizumab in patients with generalized myasthenia gravis by time from diagnosis: A post hoc subgroup analysis of the CHAMPION MG study.
8/2023	Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension.
6/2023	Ravulizumab pharmacokinetics and pharmacodynamics in patients with generalized myasthenia gravis.
1/2023	Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study.
1/2023	Ravulizumab in Myasthenia Gravis: A Review of the Current Evidence.
1/2023	Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study.
1/2021	Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
1/2021	Eculizumab during Pregnancy in a Patient with Treatment-Refractory Myasthenia Gravis: A Case Report.
1/2020	Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial.
1/2019	Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Tuan Vu Research Topics

Disease

17	Myasthenia Gravis 02/2024 - 01/2019
4	Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) 11/2023 - 01/2016
4	Body Weight (Weight, Body) 08/2023 - 10/2022
3	Nausea 10/2022 - 12/2014
2	Muscle Weakness 01/2024 - 01/2023
2	Autoimmune Diseases (Autoimmune Disease) 01/2024 - 01/2023
2	Clinical Deterioration 08/2023 - 10/2022
2	Fever (Fevers) 01/2023 - 10/2022
2	Headache (Headaches) 01/2023 - 10/2022
2	Fatigue 01/2021 - 04/2018
2	Multiple Sclerosis 04/2018 - 12/2014
1	Rare Diseases (Rare Disease) 10/2023
1	Meningococcal Infections 08/2023
1	Portal Hypertension 04/2023
1	Hepatitis 04/2023
1	Fibrosis (Cirrhosis) 04/2023
1	Ascites 04/2023
1	Varicose Veins (Varicose Vein) 04/2023
1	Hepatic Encephalopathy 04/2023
1	COVID-19 01/2023
1	Infections 01/2023
1	Neoplasms (Cancer) 01/2023
1	Dermatomyositis (Dermatopolymyositis) 10/2022
1	Thromboembolism 10/2022
1	Breast Neoplasms (Breast Cancer) 04/2022
1	Peripheral Nervous System Diseases (PNS Diseases) 04/2022
1	Pain (Aches) 01/2021
1	Neuralgia (Stump Neuralgia) 01/2021
1	Polyneuropathies (Polyneuropathy) 01/2021
1	Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) 01/2021
1	Migraine Disorders (Migraine) 12/2014
1	Tics (Tic) 12/2014
1	Intractable Pain 12/2014
1	Tremor (Tremors) 12/2014
1	Vomiting 12/2014
1	Weight Loss (Weight Reduction) 12/2014
1	Glaucoma 12/2014
1	Epilepsy (Aura) 12/2014
1	Dystonia (Limb Dystonia) 12/2014
1	Dizziness (Lightheadedness) 12/2014

Drug/Important Bio-Agent (IBA)

10	Cholinergic ReceptorsIBA 02/2024 - 01/2019
9	glucose-mannose-glucoseIBA 02/2024 - 01/2019
7	AutoantibodiesIBA 01/2024 - 01/2019
6	ravulizumabIBA 02/2024 - 05/2022
3	zilucoplanIBA 01/2024 - 01/2020
3	Complement Inactivating AgentsIBA 10/2023 - 01/2020
2	Immunoglobulin G (IgG)IBA 01/2024 - 01/2021
2	salicylhydroxamic acid (SHAM)IBA 11/2023 - 01/2019
2	neonatal Fc receptorIBA 01/2023 - 01/2019
2	Intravenous Immunoglobulins (IVIG)FDA Link 10/2022 - 01/2021
2	Immunoglobulin Fc FragmentsIBA 01/2021 - 01/2019
2	Immunoglobulins (Immunoglobulin)IBA 01/2021 - 01/2019
1	4-(3-chlorophenylsulfanyl)piperidineIBA 04/2023
1	Complement Membrane Attack Complex (Membrane Attack Complex)IBA 01/2023
1	muskIBA 01/2023
1	bis(3- bis(4- chlorophenyl)methyl- 4- dimethylaminophenyl)amineIBA 01/2023
1	Chimeric Antigen ReceptorsIBA 01/2023
1	Complement System Proteins (Complement)IBA 01/2023
1	DNA (Deoxyribonucleic Acid)IBA 01/2023
1	Phosphotransferases (Kinase)IBA 01/2023
1	RNA (Ribonucleic Acid)IBA 01/2023
1	Biomarkers (Surrogate Marker)IBA 01/2023
1	rozanolixizumabIBA 01/2023
1	B-Cell Maturation AntigenIBA 01/2023
1	Acetylcholine (Acetylcholine Chloride)FDA Link 05/2022
1	taxaneIBA 04/2022
1	Antidepressive Agents (Antidepressants)IBA 01/2021
1	Nortriptyline (Aventyl)FDA LinkGeneric 01/2021
1	Pregabalin (Lyrica)FDA Link 01/2021
1	Duloxetine Hydrochloride (Cymbalta)FDA Link 01/2021
1	Mexiletine (Mexitil)FDA LinkGeneric 01/2021
1	Anticonvulsants (Antiepileptic Drugs)IBA 01/2021
1	Sodium Channel BlockersIBA 01/2021
1	eculizumab FDA Link 01/2021
1	reldesemtivIBA 01/2021
1	Monoclonal AntibodiesIBA 01/2021
1	AgrinIBA 01/2020
1	Natalizumab (Tysabri)FDA Link 04/2018
1	Central Nervous System Depressants (CNS Depressants)IBA 12/2014
1	Opioid Analgesics (Opioids)IBA 12/2014
1	CannabinoidsIBA 12/2014

Therapy/Procedure

11	Activities of Daily Living (ADL) 02/2024 - 01/2019
4	Therapeutics 01/2023 - 04/2018
3	Resistance Training 11/2023 - 01/2016
1	Drug Therapy (Chemotherapy) 04/2022